Hydrocortison Fna Fagron (Hydrocortisone Acetate)

Hydrocortison Fna Fagron is indicated for the topical treatment of several inflammatory skin disorders. It helps reduce redness, swelling, and itching associated with these conditions.

• Mild to moderate eczema (atopic dermatitis) to relieve itching and inflammation
• Contact dermatitis caused by irritants or allergens to decrease erythema
• Psoriasis plaques to soften scaling and reduce inflammation
• Seborrheic dermatitis on scalp or face to control flaking and redness
• Other inflammatory dermatoses such as lichen planus to alleviate lesions

• Hydrocortison Fna Fagron delivers hydrocortisone acetate to the skin, where it diffuses into epidermal and dermal cells and binds to intracellular glucocorticoid receptors. The receptor‑ligand complex translocates to the nucleus and interacts with glucocorticoid response elements, modulating gene transcription. This results in decreased synthesis of pro‑inflammatory cytokines, prostaglandins, and leukotrienes, and suppresses the activity of immune cells, thereby reducing inflammation and immune responses in the treated area.

Topical hydrocortisone acetate may cause local and, rarely, systemic adverse reactions.

Common

• Burning, stinging, or itching at the application site
• Dryness or peeling of the skin
• Redness or mild irritation
• Folliculitis or acneiform eruptions
• Increased itching or pruritus at the site
• Excessive hair growth (hypertrichosis) in the treated area
• Skin discoloration or hypopigmentation

Serious

• Skin atrophy or thinning with prolonged use
• Telangiectasia (visible small blood vessels)
• Secondary bacterial, fungal, or viral infection of the treated area
• Allergic contact dermatitis to the formulation
• Suppression of the hypothalamic‑pituitary‑adrenal (HPA) axis with extensive or prolonged application
• Systemic corticosteroid effects (e.g., Cushingoid features, hyperglycemia) if absorbed in large amounts

When using Hydrocortison Fna Fagron, certain precautions should be observed to minimize risks and ensure safe therapy.

• Avoid application on broken, infected, or ulcerated skin unless directed by a clinician.
• Limit duration of use, typically not exceeding two weeks, to reduce the chance of skin atrophy.
• Do not use under occlusive dressings unless specifically prescribed.
• Exercise caution in patients with diabetes, hypertension, or known sensitivity to corticosteroids.
• Pregnant or breastfeeding women should consult a healthcare professional before use.
• Children may be more susceptible to systemic absorption; use the lowest effective amount.

Hydrocortison Fna Fagron may interact with other topical or systemic agents; consider the following guidance.

Avoid

• Concurrent use with other potent topical corticosteroids on the same area, which can increase systemic absorption.
• Application together with skin‑irritating products such as chemical peels, retinoids, or abrasive cleansers.
• Use with topical calcineurin inhibitors (e.g., tacrolimus) on the same site, as combined immunosuppression may increase infection risk.

Use with caution

• Systemic corticosteroids or oral immunosuppressants, as combined effects may enhance immunosuppression.
• Antifungal or antibacterial creams, because altered skin barrier may affect drug penetration.
• Phototherapy (UVB/UVA) treatments, which may increase skin sensitivity when combined with corticosteroids.